<DOC>
	<DOC>NCT02342067</DOC>
	<brief_summary>A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.</brief_summary>
	<brief_title>Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination</brief_title>
	<detailed_description>This is a open-label, fixed-sequence, 3-period study being conducted in a single center to evaluate the following: - PK of CVC administered with and without PGZ - PK of PGZ administered with and without CVC - Safety of CVC administered with and without PGZ - Tolerability of CVC administered with and without PGZ</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Provide written informed consent BMI ≥ 18 and ≤ 35 kg/m2 No clinically relevant abnormalities based on medical history, physical examination, clinical laboratory evaluations, and 12lead ECG Agree to comply with the study procedures and restrictions Any disease or condition that might affect drug absorption, metabolism, or excretion, or clinically significant conditions as determined by the investigator History of stomach or intestinal surgery, except for fully healed appendectomy and/or cholecystectomy Serum ALT, AST or bilirubin ≥ grade 1 (ALT and AST &gt; ULN 3.0 x ULN; bilirubin &gt; ULN 1.5 x ULN) at screening Positive for HIV, HBV or HCV infection Use of any prescription drugs or prohibited medications within 30 days from the first dose of the study medication Use of alcoholcontaining or caffeinecontaining foods or beverages within 72 hours prior to the first dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>